Skip to main content
SpringerLink
Log in

Rituximab in the treatment of systemic sclerosis-associated interstitial lung disease: Comment on the article by Yoo

  • Letter to the Editor
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Several lines of evidence from basic research indicate that B cells may contribute to the pathogenesis of systemic sclerosis. Clinical studies as well have provided preliminary data pointing to the direction that B-cell depletion with rituximab might be a therapeutic option for patients with this debilitating disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C et al (2010) Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 49:271–280

    Article  CAS  Google Scholar 

  2. Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ et al (2009) B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 60:578–583

    Article  PubMed  Google Scholar 

  3. Smith V, Van Praet JT, Vandooren B, Van der Cruyssen B, Naeyaert JM, Decuman S et al (2010) Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 69:193–197

    Article  PubMed  CAS  Google Scholar 

  4. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Korfiatis P et al. (2009) Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature. Semin Arthritis Rheum 2009. Epub ahead of print

  5. Simms RW, Lafyatis R (2010) Rituximab: a potential therapeutic advance in scleroderma: what is the evidence? Rheumatology (Oxford) 49:201–202

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Department of Internal Medicine, Patras University Hospital, University of Patras Medical School, 26504, Rion, Patras, Greece

    Dimitrios Daoussis & Andrew P. Andonopoulos

Authors
  1. Dimitrios Daoussis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew P. Andonopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dimitrios Daoussis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Daoussis, D., Andonopoulos, A.P. Rituximab in the treatment of systemic sclerosis-associated interstitial lung disease: Comment on the article by Yoo. Rheumatol Int 31, 841–842 (2011). https://doi.org/10.1007/s00296-010-1485-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-010-1485-3

Keywords

Search

Navigation